Pfizer reported Q1 2026 revenue of $14.5 billion, beating estimates with a 5% year-over-year increase driven by strong sales in launched and acquired products. Adjusted EPS was $0.75, above the $0.72 consensus. Key drugs like Padcev, Nurtec ODT, and Lorbrena showed double-digit growth, while COVID-19 products Comirnaty and Paxlovid declined significantly. Pfizer reaffirmed its full-year revenue guidance of $59.5-$62.5 billion and adjusted EPS of $2.80-$3, highlighting ongoing pipeline progress in oncology and obesity.
Pharmaceutical companies are investing over $1 billion in AI technologies to advance bispecific antibody development, aiming to mitigate clinical risks and manufacturing challenges. AI platforms help optimize dual-target engagement, predict immune re...
At the American Diabetes Association conference, leading drugmakers like Eli Lilly and Novo Nordisk showcased new obesity treatments including advanced GLP-1 pills and shots promising greater weight loss and easier dosing schedules. Eli Lilly's exper...
Eli Lilly's stock has surged over 20% recently, driven mainly by two obesity drugs, Mounjaro and Zepbound, but this growth is risky due to heavy reliance on few products and price pressures. Investors are paying high multiples amid peak hype, which m...
Pfizer is undergoing a major transformation, relying on new oncology and obesity assets to offset declining COVID revenues and patent losses. The company offers a 6.7% dividend yield with a payout ratio of about 53% of earnings, but free cash flow co...
Pfizer trades at $25.60 with a 6.7% dividend yield, reflecting market caution amid its transition from COVID products to oncology and obesity drugs. Despite strong earnings beats and a low forward P/E, the company faces challenges including declining...
